McGuire DK, Busui RP, Deanfield J, Inzucchi SE, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL, a randomized trial, design and baseline characteristics. Diabetes Obes Metab 2023 Mar 21. doi: 10.1111/dom.15058.
PMID: 36945734